Symbols / ATYR Stock $0.50 -3.83% aTyr Pharma, Inc.

Healthcare • Biotechnology • United States • NCM
ATYR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Sanjay S. Shukla M.D., M.S.
Exch · Country NCM · United States
Market Cap 49.04M
Enterprise Value -5.97M
Income -70.03M
Sales 190.00K
FCF (ttm) -32.65M
Book/sh 0.59
Cash/sh 0.68
Employees 58
Insider 10d —
IPO May 07, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.78
PEG —
P/S 258.08
P/B 0.85
P/C —
EV/EBITDA 0.08
EV/Sales -31.42
Quick Ratio 5.73
Current Ratio 5.78
Debt/Eq 20.26
LT Debt/Eq —
EPS (ttm) -0.74
EPS next Y -0.64
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-15
ROA -51.79%
ROE -105.63%
ROIC —
Gross Margin 0.00%
Oper. Margin -385.74%
Profit Margin 0.00%
Shs Outstand 98.05M
Shs Float 95.61M
Insider Own 2.45%
Instit Own 57.51%
Short Float 25.14%
Short Ratio 7.76
Short Interest 21.39M
52W High 7.29
vs 52W High -93.14%
52W Low 0.40
vs 52W Low 26.61%
Beta 0.66
Impl. Vol. 3.34%
Rel Volume 0.78
Avg Volume 2.20M
Volume 1.71M
Target (mean) $2.86
Tgt Median $3.00
Tgt Low $1.00
Tgt High $7.00
# Analysts 7
Recom Buy
Prev Close $0.52
Price $0.50
Change -3.83%
About

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$2.86
Mean price target
2. Current target
$0.50
Latest analyst target
3. DCF / Fair value
$-5.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.50
Low
$1.00
High
$7.00
Mean
$2.86

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-20 up Freedom Broker Hold → Buy $4
2025-11-07 main RBC Capital Sector Perform → Sector Perform $1
2025-09-16 down Wells Fargo Overweight → Equal-Weight $1
2025-09-16 down RBC Capital Outperform → Sector Perform $2
2025-09-15 down HC Wainwright & Co. Buy → Neutral —
2025-09-15 down Leerink Partners Outperform → Market Perform $1
2025-09-15 down Jones Trading Buy → Hold —
2025-09-15 down Cantor Fitzgerald Overweight → Neutral —
2025-09-15 down LUCID CAPITAL MARKETS Buy → Neutral $1
2025-08-22 main Jefferies Buy → Buy $17
2025-06-20 main Wells Fargo Overweight → Overweight $25
2025-06-04 reit HC Wainwright & Co. Buy → Buy $35
2025-05-19 reit HC Wainwright & Co. Buy → Buy $35
2025-03-14 reit HC Wainwright & Co. Buy → Buy $35
2025-02-18 init Leerink Partners — → Outperform $16
2025-01-06 init Cantor Fitzgerald — → Overweight —
2024-12-10 reit HC Wainwright & Co. Buy → Buy $35
2024-12-03 reit HC Wainwright & Co. Buy → Buy $35
2024-10-29 reit HC Wainwright & Co. Buy → Buy $35
2024-10-04 init Wells Fargo — → Overweight $17
News
RSS: Latest ATYR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-27 SCHIMMEL PAUL R Director — 100,000 $0.50 $49,630
2026-02-04 BROADFOOT JILL MARIE Chief Financial Officer — 1,558 $0.98 $1,521
2026-02-04 SHUKLA SANJAY S Chief Executive Officer — 3,745 $0.98 $3,655
2026-02-04 DENYES NANCY General Counsel — 1,118 $0.98 $1,091
2026-02-03 BROADFOOT JILL MARIE Chief Financial Officer — 3,750 — —
2026-02-03 SHUKLA SANJAY S Chief Executive Officer — 10,375 — —
2026-02-03 DENYES NANCY General Counsel — 2,687 — —
2025-10-09 SCHIMMEL PAUL R Director — 1,000,000 $0.90 $911,801
2025-03-17 GROSS JANE A Director — 3,750 $4.00 $15,000
2025-02-04 BROADFOOT JILL MARIE Chief Financial Officer — 1,254 $3.78 $4,740
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.19
-19.15%
0.23
-33.43%
0.35
-96.60%
10.39
Operating Revenue
0.19
-19.15%
0.23
-33.43%
0.35
-96.60%
10.39
Operating Expense
77.82
+14.19%
68.15
+23.30%
55.27
-2.67%
56.79
Research And Development
60.22
+10.75%
54.37
+28.56%
42.29
-1.20%
42.81
Selling General And Administration
17.60
+27.73%
13.78
+6.15%
12.98
-7.17%
13.98
General And Administrative Expense
17.60
+27.73%
13.78
+6.15%
12.98
-7.17%
13.98
Other Gand A
17.60
+27.73%
13.78
+6.15%
12.98
-7.17%
13.98
Total Expenses
77.82
+14.19%
68.15
+23.30%
55.27
-2.67%
56.79
Operating Income
-77.63
-14.30%
-67.91
-23.66%
-54.92
-18.35%
-46.40
Total Operating Income As Reported
-77.63
-14.30%
-67.91
-23.66%
-54.92
-18.35%
-46.40
EBITDA
-76.07
-14.61%
-66.37
-27.21%
-52.18
-16.71%
-44.71
Normalized EBITDA
-76.07
-14.61%
-66.37
-27.21%
-52.18
-16.71%
-44.71
Reconciled Depreciation
1.55
+0.84%
1.54
-43.82%
2.74
+61.71%
1.70
EBIT
-77.63
-14.30%
-67.91
-23.66%
-54.92
-18.35%
-46.40
Net Income
-74.12
-15.77%
-64.02
-27.06%
-50.39
-11.14%
-45.34
Pretax Income
-74.12
-15.78%
-64.02
-27.04%
-50.40
-11.15%
-45.34
Other Income Expense
3.50
-9.97%
3.89
-13.93%
4.52
+326.20%
1.06
Other Non Operating Income Expenses
3.50
-9.97%
3.89
-13.93%
4.52
+326.20%
1.06
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-74.12
-15.78%
-64.02
-27.04%
-50.40
-11.15%
-45.34
Net Income From Continuing Operation Net Minority Interest
-74.12
-15.77%
-64.02
-27.06%
-50.39
-11.14%
-45.34
Net Income From Continuing And Discontinued Operation
-74.12
-15.77%
-64.02
-27.06%
-50.39
-11.14%
-45.34
Net Income Continuous Operations
-74.12
-15.78%
-64.02
-27.04%
-50.40
-11.15%
-45.34
Minority Interests
0.01
+600.00%
-0.00
-112.50%
0.01
+60.00%
0.01
Normalized Income
-74.12
-15.77%
-64.02
-27.06%
-50.39
-11.14%
-45.34
Net Income Common Stockholders
-74.12
-15.77%
-64.02
-27.06%
-50.39
-11.14%
-45.34
Diluted EPS
—
-0.86
+8.51%
-0.94
+41.25%
-1.60
Basic EPS
—
-0.86
+8.51%
-0.94
+41.25%
-1.60
Basic Average Shares
—
74.26
+38.53%
53.61
+88.63%
28.42
Diluted Average Shares
—
74.26
+38.53%
53.61
+88.63%
28.42
Diluted NI Availto Com Stockholders
-74.12
-15.77%
-64.02
-27.06%
-50.39
-11.14%
-45.34
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
93.00
-3.95%
96.83
-19.75%
120.65
+25.96%
95.79
Current Assets
80.24
-2.10%
81.95
-20.43%
102.99
+27.35%
80.87
Cash Cash Equivalents And Short Term Investments
78.69
+9.10%
72.12
-26.53%
98.17
+48.41%
66.15
Cash And Cash Equivalents
10.74
-2.82%
11.05
-50.96%
22.54
+125.87%
9.98
Cash Equivalents
7.92
-17.38%
9.58
-55.70%
21.63
+151.90%
8.59
Cash Financial
2.83
+91.79%
1.47
+60.57%
0.92
-34.24%
1.40
Other Short Term Investments
67.94
+11.26%
61.07
-19.24%
75.62
+34.64%
56.16
Receivables
0.87
-49.71%
1.74
-28.74%
2.44
-79.31%
11.78
Other Receivables
0.87
-49.71%
1.74
-28.74%
2.44
-79.31%
11.78
Prepaid Assets
0.68
-91.63%
8.09
+238.62%
2.39
-18.98%
2.95
Other Current Assets
—
—
—
2.95
Total Non Current Assets
12.77
-14.18%
14.88
-15.77%
17.66
+18.41%
14.91
Net PPE
10.38
-12.45%
11.86
-15.57%
14.05
+21.54%
11.56
Gross PPE
15.21
-7.26%
16.40
-12.14%
18.67
+4.22%
17.91
Accumulated Depreciation
-4.83
-6.30%
-4.54
+1.71%
-4.62
+27.27%
-6.35
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
5.52
-5.04%
5.82
-13.53%
6.73
-7.21%
7.25
Machinery Furniture Equipment
0.47
+7.50%
0.44
-1.79%
0.45
-27.74%
0.62
Other Properties
3.56
-20.71%
4.49
-23.09%
5.84
+3.77%
5.63
Leases
5.65
+0.00%
5.65
+0.00%
5.65
+28.07%
4.41
Other Non Current Assets
2.38
-21.01%
3.02
-16.54%
3.62
+7.65%
3.36
Total Liabilities Net Minority Interest
25.71
-4.75%
27.00
-10.55%
30.18
+23.19%
24.50
Current Liabilities
15.15
+1.21%
14.97
-8.83%
16.42
+18.42%
13.86
Payables And Accrued Expenses
13.68
-0.24%
13.71
-9.10%
15.09
+16.35%
12.97
Payables
3.89
-9.99%
4.32
+22.50%
3.53
+13.62%
3.11
Accounts Payable
3.89
-9.99%
4.32
+22.50%
3.53
+13.62%
3.11
Current Accrued Expenses
9.79
+4.25%
9.39
-18.75%
11.56
+17.21%
9.86
Current Debt And Capital Lease Obligation
1.47
+17.09%
1.25
-5.72%
1.33
+48.55%
0.89
Current Capital Lease Obligation
1.47
+17.09%
1.25
-5.72%
1.33
+48.55%
0.89
Total Non Current Liabilities Net Minority Interest
10.57
-12.17%
12.03
-12.61%
13.77
+29.39%
10.64
Long Term Debt And Capital Lease Obligation
10.57
-12.17%
12.03
-12.61%
13.77
+29.39%
10.64
Long Term Capital Lease Obligation
10.57
-12.17%
12.03
-12.61%
13.77
+29.39%
10.64
Stockholders Equity
67.48
-3.63%
70.02
-22.77%
90.66
+26.86%
71.46
Common Stock Equity
67.48
-3.63%
70.02
-22.77%
90.66
+26.86%
71.46
Capital Stock
0.10
+16.67%
0.08
+33.33%
0.06
+117.24%
0.03
Common Stock
0.10
+16.67%
0.08
+33.33%
0.06
+117.24%
0.03
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
98.03
+16.65%
84.04
+32.79%
63.29
+114.54%
29.50
Ordinary Shares Number
98.03
+16.65%
84.04
+32.79%
63.29
+114.54%
29.50
Additional Paid In Capital
673.55
+11.88%
602.02
+7.76%
558.69
+14.13%
489.50
Retained Earnings
-606.16
-13.93%
-532.05
-13.68%
-468.02
-12.07%
-417.63
Gains Losses Not Affecting Retained Earnings
-0.01
+80.00%
-0.04
+45.95%
-0.07
+82.91%
-0.43
Minority Interest
-0.19
-2.67%
-0.19
+0.53%
-0.19
-4.44%
-0.18
Other Equity Adjustments
-0.01
+80.00%
-0.04
+45.95%
-0.07
+82.91%
-0.43
Total Equity Gross Minority Interest
67.29
-3.64%
69.83
-22.81%
90.47
+26.91%
71.28
Total Capitalization
67.48
-3.63%
70.02
-22.77%
90.66
+26.86%
71.46
Working Capital
65.09
-2.83%
66.99
-22.63%
86.58
+29.20%
67.01
Invested Capital
67.48
-3.63%
70.02
-22.77%
90.66
+26.86%
71.46
Total Debt
12.03
-9.41%
13.28
-12.00%
15.10
+30.87%
11.53
Capital Lease Obligations
12.03
-9.41%
13.28
-12.00%
15.10
+30.87%
11.53
Net Tangible Assets
67.48
-3.63%
70.02
-22.77%
90.66
+26.86%
71.46
Tangible Book Value
67.48
-3.63%
70.02
-22.77%
90.66
+26.86%
71.46
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-61.99
+10.32%
-69.12
-108.06%
-33.22
+20.69%
-41.89
Cash Flow From Continuing Operating Activities
-61.99
+10.32%
-69.12
-108.06%
-33.22
+20.69%
-41.89
Net Income From Continuing Operations
-74.12
-15.78%
-64.02
-27.04%
-50.40
-11.15%
-45.34
Depreciation Amortization Depletion
1.55
+0.84%
1.54
-43.82%
2.74
+61.71%
1.70
Depreciation
1.55
+0.84%
1.54
-43.82%
2.74
+61.71%
1.70
Depreciation And Amortization
1.55
+0.84%
1.54
-43.82%
2.74
+61.71%
1.70
Other Non Cash Items
—
—
—
—
Stock Based Compensation
5.00
+67.18%
2.99
+14.96%
2.60
+20.71%
2.15
Operating Gains Losses
-0.01
-300.00%
-0.00
+50.00%
-0.01
+93.48%
-0.09
Gain Loss On Sale Of PPE
-0.01
-300.00%
-0.00
+50.00%
-0.01
+93.48%
-0.09
Change In Working Capital
7.45
+207.73%
-6.92
-146.08%
15.01
+1902.16%
-0.83
Change In Receivables
0.86
+114.68%
0.40
-95.56%
9.05
+175.94%
-11.92
Change In Prepaid Assets
7.33
+230.08%
-5.64
-1006.43%
0.62
-72.21%
2.24
Change In Payables And Accrued Expense
-0.03
+97.54%
-1.34
-141.05%
3.26
-51.61%
6.74
Change In Other Current Liabilities
-0.71
-107.29%
-0.34
-116.54%
2.07
-1.75%
2.11
Investing Cash Flow
-5.05
-129.32%
17.23
+185.62%
-20.13
-142.60%
47.24
Cash Flow From Continuing Investing Activities
-5.05
-129.32%
17.23
+185.62%
-20.13
-142.60%
47.24
Net PPE Purchase And Sale
-0.07
-12.07%
-0.06
+98.62%
-4.20
-187.28%
-1.46
Purchase Of PPE
-0.08
-18.46%
-0.07
+98.46%
-4.21
-156.86%
-1.64
Sale Of PPE
0.01
+71.43%
0.01
-53.33%
0.01
-91.62%
0.18
Capital Expenditure
-0.08
-18.46%
-0.07
+98.46%
-4.21
-156.86%
-1.64
Net Investment Purchase And Sale
-4.99
-128.85%
17.29
+208.56%
-15.93
-132.70%
48.71
Purchase Of Investment
-93.44
-35.23%
-69.10
+35.40%
-106.98
-153.99%
-42.12
Sale Of Investment
88.46
+2.39%
86.39
-5.11%
91.05
+0.25%
90.83
Financing Cash Flow
66.01
+65.59%
39.86
-39.81%
66.23
+1115.01%
5.45
Cash Flow From Continuing Financing Activities
66.01
+65.59%
39.86
-39.81%
66.23
+1115.01%
5.45
Net Issuance Payments Of Debt
-0.54
-8.45%
-0.50
-26.14%
-0.39
-496.97%
-0.07
Repayment Of Debt
-0.54
-8.45%
-0.50
-26.14%
-0.39
-496.97%
-0.07
Long Term Debt Payments
-0.54
-8.45%
-0.50
-26.14%
-0.39
-496.97%
-0.07
Net Long Term Debt Issuance
-0.54
-8.45%
-0.50
-26.14%
-0.39
-496.97%
-0.07
Net Common Stock Issuance
66.42
+64.98%
40.26
-39.47%
66.52
+1115.63%
5.47
Proceeds From Stock Option Exercised
0.13
+27.00%
0.10
-4.76%
0.10
+133.33%
0.04
Changes In Cash
-1.03
+91.45%
-12.02
-193.32%
12.88
+19.17%
10.81
Beginning Cash Position
14.01
-46.19%
26.03
+97.99%
13.15
+462.76%
2.34
End Cash Position
12.98
-7.34%
14.01
-46.19%
26.03
+97.99%
13.15
Free Cash Flow
-62.06
+10.29%
-69.18
-84.81%
-37.44
+13.99%
-43.53
Interest Paid Supplemental Data
0.09
-31.39%
0.14
-20.35%
0.17
+218.52%
0.05
Amortization Of Securities
-1.85
+31.46%
-2.71
+14.70%
-3.17
-694.93%
0.53
Common Stock Issuance
66.42
+64.98%
40.26
-39.47%
66.52
+1115.63%
5.47
Issuance Of Capital Stock
66.42
+64.98%
40.26
-39.47%
66.52
+1115.63%
5.47
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category